SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2009
Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Guideline
- Management of malignant bowel obstruction in patients with advanced cancer at the end of life.Radiology and oncology · 2026Review
- Palliative management of malignant gastric outlet obstruction: A practice review.Palliative medicine · 2026Review
- Non-surgical management of malignant bowel obstruction: strategies and outcomes in inoperable patients.Journal of gastrointestinal oncology · 2026Article
- Malignant Bowel Obstruction Management Over Time: Are We Doing Anything New? A Current Narrative Review.Annals of surgical oncology · 2022Review
- The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations.Annals of surgical oncology · 2020Article
- Updates in palliative care - recent advancements in the pharmacological management of symptoms.Clinical medicine (London, England) · 2018Review
- Treatment Options in Gastrointestinal Cutaneous Fistulas.Surgery journal (New York, N.Y.) · 2017Review
- Management of intestinal obstruction in advanced malignancy.Annals of medicine and surgery (2012) · 2015Review
- Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution.Cancer management and research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
goals of workInoperable bowel obstructions are not uncommon in advanced cancer and are associated with a very poor prognosis. Symptom control includes reducing the frequency of vomiting by prescription of antisecretory medications. The most commonly used agents for this are either hyoscine butylbromide or octreotide. Either histamine 2 antagonists or proton pump inhibitors are sometimes recommended as adjuvants to reduce gastric secretions. The aim of this study was to examine the effects of histamine 2 antagonists and proton pump inhibitors and to objectively compare the effects of one agent over another. MATERIALS AND
methodsPreviously, electronic databases were searched for trials that compared ranitidine versus proton pump inhibitors in their effect on volume of gastric aspirates.
resultsSeven trials were included in a meta-analysis. Pooled outcomes suggest that both proton pump inhibitors and ranitidine reduce gastric volumes, but the most superior agent is ranitidine, which reduces the volume of gastric secretions by an average of 0.22 ml.kg(-1); 95% confidence interval 0.04 to 0.41.
conclusionsBased on well-conducted studies, objective evidence exists that confirms ranitidine will decrease the volume of gastric aspirates. This forms a sound basis from which to develop further research aimed at improving the care of people with malignant bowel obstructions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.